Translational Cancer Medicine

Level

Translational Cancer Medicine

King's College London
Logo King's College London

Need more information? Get more details on the site of the provider.

Starting dates and places

There are no known starting dates for this product.

Description

Translational Cancer Medicine enables you to gain detailed knowledge and understanding of research methods applied to rational drug design, clinical study design, molecular and cell biology, tumour immunology, genetics and cancer imaging. Practical experience gained through two six-month laboratory rotations.
KEY BENEFITS

  • The range of topics including advanced imaging methods is unique for this translational cancer programme.
  • The sponsoring laboratories and departments all have international standing and have agreed to closely supervise the trainees.
  • Figures released in October 2007 by The Higher Education Funding Council for England (HEFCE) show that King's College London is the most succe…

Read the complete description

Frequently asked questions

There are no frequently asked questions yet. If you have any more questions or need help, contact our customer service.

Didn't find what you were looking for? See also: Medicine, EC-Council, Infection Control, Advanced Practice, and Acute Care.

Translational Cancer Medicine enables you to gain detailed knowledge and understanding of research methods applied to rational drug design, clinical study design, molecular and cell biology, tumour immunology, genetics and cancer imaging. Practical experience gained through two six-month laboratory rotations.
KEY BENEFITS

  • The range of topics including advanced imaging methods is unique for this translational cancer programme.
  • The sponsoring laboratories and departments all have international standing and have agreed to closely supervise the trainees.
  • Figures released in October 2007 by The Higher Education Funding Council for England (HEFCE) show that King's College London is the most successful university in the country in terms of PhD completion rates and this programme will potentially select candidates for the PhD programme within the Division of Cancer Studies.

PURPOSEThe programme will provide students with a detailed knowledge and understanding of research methods applied to rational drug design, clinical study design, molecular and cell biology, tumour immunology, genetics and cancer imaging, all of which are relevant to Translational Cancer Research. In addition practical experience will be gained through two laboratory rotations of six months duration.

DESCRIPTION

Overview of subjects covered:

  • Biomarkers, Biostatistics and Modelling
  • Breast Cancer
  • Cancer Bioinformatics
  • Cancer Imaging (Optical)
  • Cancer Imaging (PET)
  • Clinical Trials and translational research
  • Gene discovery through to therapeutic applications
  • Haemato-oncology and associated genetics/genomics
  • Immunology of Cancers
  • Molecular Pathology
  • Signal Transduction in cancers.
Project titles:
  • Applications of novel coincidence detection technology to the analysis of signalling networks in tumours
  • Roles of RhoGTPases in cancer cell interaction with endothelial cells
  • Prostate cancer care and outcomes in England
  • Analysis of the interaction between neoplastic B cells and the microvascular endothelium in patients with chronic lymphocytic leukaemia
  • Proteomic analyses of leukaemia
  • SNP and MicroRNA profiling pre and post DNMT inhibitor and immunomodulatory therapy in Low Risk MDS
  • Peptide based vaccination against tumour associated antigens
  • Understanding the role of c-Met targeting in improving epidermal growth factor receptor (EGFR)-focused therapy in triple negative breast cancer patients
  • Positron emitting copper complexes for imaging CXCR4 receptor expression in tumours
  • Molecular pathology of breast cancer precursors
  • Impact of cellular preservation and processes on translational research
  • Investigating DNA damage response phenotypes in triple negative breast cancers as potential biomarkers of therapy response
  • Changes in post-translational modifications (O-linked glycosylation) of breast cancer: The effect on tumour behaviour and immune recognition
  • Eipigenetics and breast cancer: The role of JARID1B, a histone demethylase
  • Delivery of antigens and adjuvants to dendritic cells for tumour immunotherapy.
  • Adoptive immunotherapy of cancer using genetically targeted T-cells.
  • Detection of immune reactivity against MUC1 and ErbB2 in breast cancer.
  • Drug discovery and preclinical development.


EXTRA PROGRAMME INFORMATIONOccupational health clearance will be required for some of the projects.

There are no reviews yet.

Share your review

Do you have experience with this course? Submit your review and help other people make the right choice. As a thank you for your effort we will donate £1.- to Stichting Edukans.

There are no frequently asked questions yet. If you have any more questions or need help, contact our customer service.